At the cutting edge of global health innovation, where algorithms now sit beside microscopes and molecules are tested in silico before they ever meet a human cell, a quiet revolution is unfolding with Ghana beginning to stake its claim.

Ghanaian sports merchandise

On a cold March morning inside the AI in Pharmaceutical Discovery Lab at Imperial College London’s White City Campus, the future of medicine felt less like science fiction and more like a rapidly approaching reality.

For Ghanaian academic and Schmidt Global Faculty Fellow, Dr Ofosua Adi-Dako, the moment represented more than just a research placement. It was a preview of what Ghana’s pharmaceutical future could become.

Speaking during a UK knowledge transfer visit under the UK-Ghana Capacity Building for Media Excellence in Science, Technology and Innovation programme, Dr Adi-Dako described a fundamental shift in how drugs are discovered.

In traditional laboratories, research is slow, expensive, and repetitive. A single experiment can take weeks, requiring constant repetition to verify accuracy. But in the world she is now immersed in, artificial intelligence changes the tempo entirely. With AI-driven systems, she explained, researchers can analyse vast datasets in minutes, uncover hidden patterns in biological data, and predict outcomes that would take human-led processes months or even years to establish.

“What we are doing now is faster, more precise, and highly accurate,” she noted, describing how AI tools are increasingly able to simulate complex biological processes and accelerate decision-making in drug development.

At the heart of this transformation is a convergence of computational science and pharmaceutical research. AI systems can now scan enormous chemical libraries, identify promising compounds, and model how drugs interact with the human body before they are physically produced.

For Ghana, where infectious diseases such as malaria, tuberculosis, and schistosomiasis remain major public health challenges, this shift could be transformative.

A 2022 review published in PLOS Neglected Tropical Diseases by Richard Kwamla Amewu and colleagues highlights both the promise and limitations of Ghana’s drug discovery ecosystem. While the country has built a foundation in early-stage research, particularly in natural product drug discovery, progress is constrained by limited funding, infrastructural gaps, and a shortage of specialised expertise in areas like computational chemistry and pharmacokinetics.

Yet the study also points to a growing web of international collaboration involving institutions such as the University of Ghana, the Noguchi Memorial Institute for Medical Research, and the Kwame Nkrumah University of Science and Technology, signaling a system slowly positioning itself for transformation.
 
The “lab on a chip” revolution

One of the most promising technologies Dr. Adi-Dako encountered in London is the “lab on a chip,” a miniaturised platform that mimics human biological environments using microscopic volumes of fluid.

Instead of relying on large-scale laboratory setups, researchers can now replicate how drugs move through membranes, how they are absorbed, and how they behave in the body, all within a chip-sized device.

The system is cost-effective, high-throughput, and capable of generating large volumes of data in a short time. In essence, it allows scientists to test how a drug might behave in the human body long before clinical trials begin.

By combining this with AI, researchers can not only generate data faster but also interpret it more intelligently, identifying promising drug candidates with unprecedented efficiency.

For Dr Adi-Dako, the implications for Ghana are profound. The integration of AI into drug discovery, she argues, could significantly accelerate vaccine development and the search for local solutions to endemic diseases. Instead of relying solely on traditional, slow-moving research models, Ghanaian scientists could harness AI to fast-track discovery pipelines and reduce dependency on external pharmaceutical systems.

“This approach will bring faster solutions to healthcare challenges,” she explained, stressing that both short- and long-term benefits are expected.

Importantly, she emphasised that AI does not replace traditional research—it enhances it. Rather than discarding existing methods, it strengthens them by uncovering patterns that human analysis may miss.

A broader African AI vision
The conversation around AI in healthcare is not limited to laboratory innovation. It is also a policy and infrastructure question. In a June 2024 address, Prof. Samuel Kojo Kwofie of the University of Ghana called for aggressive investment in AI research, training, and infrastructure across Africa. He argued that AI could significantly reduce healthcare inequalities between urban and rural populations while accelerating disease diagnosis and drug discovery.

His research group has already developed AI-driven tools such as TubPred and EBOLApred, designed to identify potential treatments for diseases like tuberculosis and Ebola. These innovations demonstrate how African-led AI systems are already beginning to contribute to global biomedical research.

However, he also warned of structural barriers, including weak infrastructure, limited data systems, and underinvestment, that could slow Africa’s ability to fully benefit from the AI revolution.

Despite the challenges, the momentum is clear. AI is reshaping how medicine is discovered globally, and Ghana is increasingly part of that conversation. Dr Adi-Dako’s work in London represents more than individual academic advancement. It reflects a broader shift in which Ghanaian researchers are being trained within global AI ecosystems, then expected to translate that knowledge back home.

The stakes are high. If successfully integrated, AI-driven drug discovery could reduce the time it takes to develop new treatments, cut research costs, and strengthen Ghana’s capacity to respond to both existing and emerging diseases. But the transition will require more than technology transfer. It will demand sustained investment, stronger research infrastructure, and deliberate policy direction.

As the visit to Imperial College London drew to a close, one question lingered in the air: is Ghana ready for the drugs of tomorrow? The answer, as emerging research suggests, is not a simple yes or no. Ghana is not yet at the frontier, but it is no longer on the margins either.

With scientists like Dr. Ofosua Adi-Dako working at the intersection of artificial intelligence, pharmaceutical science, and global collaboration, the country is slowly stepping into a new era, one where medicines may no longer take decades to develop and where algorithms could become as essential as active ingredients.

The revolution, it seems, is already underway.